S-64315 is under clinical development by Les Laboratoires Servier and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how S-64315’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

S-64315 overview

S-64315 is under development for the treatment of acute myeloid leukaemia, myelodysplastic syndrome, relapsed or refractory multiple myeloma and acute myeloid leukaemia (AML), relapsed/refractory non-Hodgkin lymphoma, relapsed acute myeloid leukemia and refractory acute myeloid leukemia. The drug candidate is administered through intravenous route. The drug candidate targets myeloid leukemia cell differentiation protein Mcl-1.

It was under development for the treatment of relapsed and refractory lymphoma, triple-negative breast cancer, HR+/Her2 negative metastatic breast cancer

Les Laboratoires Servier overview

Les Laboratoires Servier (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. The company’s portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders, and others. The company also provides generic drugs and contract development and manufacturing services across its global network. The company also provides digital therapeutic solutions through its e-health division, WeHealth Digital Medicine. It sells products in Europe, America, Middle East, Africa, and Asia. Servier headquartered in Suresnes, Ile-de-France, France.

For a complete picture of S-64315’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.